Financial Performance - For the six months ended December 31, 2024, the revenue was approximately HKD 39,500,000, a decrease of about 20.5% compared to approximately HKD 49,700,000 for the same period in 2023[5] - The profit before tax for the same period was approximately HKD 12,900,000, down approximately 38.6% from approximately HKD 21,000,000 in the previous year[5] - The profit attributable to equity holders of the company was approximately HKD 10,100,000, representing a decrease of about 40.9% from approximately HKD 17,100,000 in the prior year[5] - The operating profit for the period was HKD 13,821,000, a decrease from HKD 21,091,000 in the same period last year[7] - The basic and diluted earnings per share for the period were HKD 2.51, down from HKD 4.28 in the previous year[9] - The total comprehensive income for the period was HKD 15,836,000, which includes a profit of HKD 17,123,000[14] - The pre-tax profit for the six months ended December 31, 2024, was HKD 10,108,000, a decline of 41% from HKD 17,123,000 in the same period of 2023[38] - Basic earnings per share for the six months ended December 31, 2024, were HKD 2.51, down from HKD 4.28 in 2023, representing a decrease of 41%[38] - Profit for the period was approximately HKD 10,100,000, a decrease of about HKD 7,000,000 or 40.9% compared to approximately HKD 17,100,000 in the previous period[66] Dividends - The interim dividend declared on February 26, 2025, for the six months ended December 31, 2024, was HKD 10,061,500, equating to HKD 0.025 per ordinary share[5] - The interim dividend declared for the six months ended December 31, 2024, was HKD 10,062,000, compared to HKD 15,000,000 for the same period in 2023, a reduction of 33%[41] - The interim dividend for the previous period was HKD 0.050 per share, indicating a 50% decrease in dividend payout[116] Assets and Equity - Total assets as of December 31, 2024, were HKD 313,699,000, a slight decrease from HKD 318,062,000 as of June 30, 2024[11] - The company's total equity increased to HKD 222,734,000 from HKD 218,326,000 as of June 30, 2024[11] - The equity attributable to the company's equity holders increased to HKD 222,734,000 as of December 31, 2024, from HKD 218,326,000 as of July 1, 2024[14] - The company’s retained earnings as of December 31, 2024, were HKD 172,469,000, compared to HKD 176,608,000 as of July 1, 2023[14] Cash Flow - The net cash generated from operating activities for the six months ended December 31, 2024, was HKD 17,610,000, compared to a net cash used of HKD 501,000 in the same period of 2023[15] - The net cash used in investing activities was HKD 5,512,000 for the six months ended December 31, 2024, an increase from HKD 1,835,000 in the previous year[15] - The net cash used in financing activities decreased to HKD 13,331,000 from HKD 16,212,000 year-on-year[15] - The company's cash and cash equivalents at the end of the period were HKD 79,868,000, up from HKD 74,723,000 at the end of the previous year[15] Revenue Breakdown - Revenue from healthcare staffing solutions for the six months ended December 31, 2024, was HKD 32,573,000, a decrease of 20% compared to HKD 40,674,000 for the same period in 2023[28] - Total revenue for the group for the six months ended December 31, 2024, was HKD 39,471,000, down 20% from HKD 49,703,000 in the previous year[28] - Revenue from healthcare staffing solutions was approximately HKD 32,600,000, a decrease of about 20.0% from HKD 40,700,000 in the previous year, primarily due to the closure of COVID-19 testing centers and reduced demand for healthcare services[55] Expenses - Total expenses for the group decreased to HKD 120,584,000 in 2024 from HKD 155,490,000 in 2023, reflecting a reduction of approximately 22%[30] - The group incurred employee benefits expenses of HKD 14,329,000 for the six months ended December 31, 2024, an increase from HKD 12,212,000 in the previous year[33] - Employee benefits expenses increased to approximately HKD 14,300,000 from HKD 12,200,000, reflecting a rise in operational costs[63] Trade Receivables and Payables - Trade receivables as of December 31, 2024, were HKD 31,809,000, down from HKD 38,907,000 as of June 30, 2024[43] - Trade receivables decreased from approximately HKD 38,900,000 to HKD 31,800,000, a reduction of about HKD 7,100,000[67] - Trade payables increased from approximately HKD 20,800,000 to HKD 21,800,000, primarily due to an increase in payables aged over 90 days[68] Employee Information - As of December 31, 2024, the company employed a total of 75 employees, up from 55 employees as of June 30, 2024[83] - Total employee costs for the period amounted to approximately HKD 14,300,000, compared to HKD 12,200,000 for the six months ended December 31, 2023[83] Corporate Governance - The company has maintained compliance with the corporate governance code throughout the reporting period[110] - The roles of the chairman and CEO are separated, in accordance with the corporate governance code[111] - The audit committee, consisting of three independent non-executive directors, reviewed the interim results and confirmed compliance with applicable accounting policies and standards[114] - The board of directors is evaluating the effectiveness of the corporate governance structure, including the potential separation of the roles of chairman and CEO[113] Strategic Initiatives - The company plans to continue expanding its healthcare staffing solutions and related services in Hong Kong[17] - The company actively seeks strategic partnerships and expansion opportunities to increase service offerings and geographic coverage[58] Shareholder Information - The company’s major shareholder, Ms. Xi Xiaozhu, holds a 67.30% equity interest in the company, representing 270,864,000 shares[90] - Gold Empress holds 270,864,000 shares, representing 67.30% of the company's equity[94] - HRnet Group Limited owns 32,000,000 shares, accounting for 8.0% of the company's equity[94] Stock Options and Incentives - The company has a stock option plan that allows for the granting of options to eligible participants, with options for 1,850,000 shares at HKD 1.44 and 2,000,000 shares at HKD 0.994[91] - The total number of shares issued by the company as of December 31, 2024, is 402,460,000[90] - The company has adopted a share incentive plan effective from June 1, 2022, which is valid for ten years[83] - The total number of unexercised share options as of July 1, 2024, is 4,700,000[100] - The total number of stock options and reward shares available for grant as of July 1, 2024, and December 31, 2024, is 37,540,000 shares each[104]
百本医护(02293) - 2025 - 中期财报